Commentary: Filling out the evidence base for treatment of attention-deficit hyperactivity disorder symptoms in children with intellectual and developmental disability: Conclusions for clinicians - A response to Simonoff et al. (2013)

Journal of Child Psychology and Psychiatry and Allied Disciplines

Volumn 54, Issue 6, 2013, Pages 701-703

  Eugene Arnold, L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; MALE; NOTE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; INTELLECTUAL DISABILITY; MALE; METHYLPHENIDATE;

EID: 84878061840     PISSN: 00219630     EISSN: 14697610     Source Type: Journal    
DOI: 10.1111/jcpp.12097     Document Type: Letter

References (8)

1. Aman, M.G., Buican, B., &, Arnold, L.E., (2003). Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13, 29-40.
2. Arnold, L.E., (2000). Methylphenidate vs. amphetamine: Comparative review. Journal of Attention Disorders, 3, 200-211.
3. Arnold, L.E., Aman, M.G., Cook, A.M., Witwer, A.N., Hall, K.L., Thompson, S., &, Ramadan, Y., (2006). Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1196-1205.
4. MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry, 56, 1073-86.
5. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2002). Randomized clinical trial of risperidone for irritability in autism. New England Journal of Medicine, 347, 314-321.
6. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. (2005). A randomized controlled crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62, 1266-1274.
7. Santosh, P.J., Taylor, E., Swanson, J., Wigal, T., Chuang, S., Davies, M., Greenhill, L.. &, Posner, M., (2005). Refining the diagnoses of inattention and overactivity syndromes: A reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clinical Neuroscience Research, 5, 307-314.
8. Simonoff, E., Taylor, E., Baird, G., Bernard, S., Chadwick, O., Liang, H.. &, Jichi, F., (2013). Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. Journal of Child Psychology and Psychiatry, 54, 527-535.